Table 3 Risk stratification of AML according To 2017 ELN recommendations [24]

Favorable

t(8;21)(q22;q22.1); RUNX1-RUNX1T1

inv (16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

Mutated NPM1 without FLT3-ITD

Mutated NPM1 with FLT3-ITD^low

Biallelic mutated CEBPA

Intermediate

Mutated NPM1 and FLT3-ITD^high

Wild-type NPM1 without FLT3-ITD

Wild-type NPM1 with FLT3-ITD^low

t(9;11)(p21.3;q23.3); MLLT3-KMT2A

Cytogenetic abnormalities not classified

Adverse

t(6;9)(p23;q34.1); DEK-NUP214

t(v;11q23.3); KMT2A rearranged

t(9;22)(q34.1;q11.2); BCR-ABL1

inv (3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1)

Complex karyotype, monosomal karyotype

-5 or del(5q); −7; −17/abn(17p)

Wild-type NPM1 and FLT3-ITD^high

Mutated RUNX1

Mutated ASXL1

Mutated TP53